Clinical Trial Update: Imatinib Mesylate in Treating Patients With Gliomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib mesylate in gliomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED